NVS - Novartis AG

NYSE - NYSE Delayed Price. Currency in USD
85.29
-0.17 (-0.20%)
At close: 4:02PM EDT

85.24 -0.04 (-0.04%)
After hours: 4:11PM EDT

Stock chart is not supported by your current browser
Previous Close85.46
Open85.31
Bid85.28 x 900
Ask85.29 x 3200
Day's Range84.92 - 85.50
52 Week Range72.30 - 94.19
Volume1,774,047
Avg. Volume1,798,156
Market Cap194.545B
Beta0.91
PE Ratio (TTM)14.50
EPS (TTM)5.88
Earnings DateN/A
Forward Dividend & Yield2.98 (3.49%)
Ex-Dividend Date2018-03-06
1y Target Est98.50
Trade prices are not sourced from all markets
  • The Wall Street Journal3 days ago

    [$$] We Can’t Afford the Drugs That Could Cure Cancer

    When I was training as an oncologist nearly three decades ago, we dreamed of curing cancer. Today, advances in cellular immunotherapy make it no longer a dream: A cure for cancer has become possible, even probable. A potential revolution in cancer care may be stymied by the high price of drugs, which suggests that we need to reconsider how we price them.

  • NVS vs. AZN: Which Stock Is the Better Value Option?
    Zacks3 days ago

    NVS vs. AZN: Which Stock Is the Better Value Option?

    NVS vs. AZN: Which Stock Is the Better Value Option?

  • Should Value Investors Pick Novartis AG (NVS) Stock?
    Zacks3 days ago

    Should Value Investors Pick Novartis AG (NVS) Stock?

    Is Novartis AG (NVS) a great pick from the value investor's perspective right now? Read on to know more.

  • The Wall Street Journal3 days ago

    [$$] Triple Set of EMA Recommendations for Novartis Drugs

    AG (NOVN.EB) drugs and one Sandoz biosimilar have received a positive European Medicines Agency recommendation, the company and the regulator said in separate statements Friday. Novartis’ Gilenya, a multiple-sclerosis drug, received a positive recommendation for the treatment of children and adolescents with the condition. If approved, the drug would be the first oral disease-modifying therapy for these patients, Novartis said, adding that a full approval would expand the age-range of patients able to use the drug.

  • Reuters3 days ago

    Spark's Luxturna blindness therapy gets European panel nod

    A European Medicines Agency panel recommended approval of Spark Therapeutics' gene therapy for blindness, a move that also boosts Swiss drugmaker Novartis that bought the rights to one of the world's costliest treatments outside the United States. The Committee for Medicinal Products for Human Use (CHMP) recommended http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/09/news_detail_003025.jsp&mid=WC0b01ac058004d5c1 voretigene neparvovec, approved as Luxturna in the United States, for patients suffering from inherited retinal dystrophy caused by RPE65 gene mutations, a rare genetic disorder that causes vision loss and usually leads to blindness.

  • TheStreet.com4 days ago

    Novartis Is Ready to Rally From a Large Base Pattern

    In this updated daily bar chart of NVS, below, we can see a strong rally from late June. In early September the 50-day line crossed above the 200-day line for what is commonly called a golden cross. The On-Balance-Volume (OBV) line turned up in July signaling more aggressive buying but has been stalled the past six weeks.

  • Eli Lilly Prices Animal Health Unit IPO at $24 Per Share
    Zacks4 days ago

    Eli Lilly Prices Animal Health Unit IPO at $24 Per Share

    Lilly (LLY) prices Elanco IPO at $24 per share which is above the expected range of $20-$23 per share.

  • Cannabis Company Tilray's (TLRY) Shares Up 856% Since July
    Zacks4 days ago

    Cannabis Company Tilray's (TLRY) Shares Up 856% Since July

    Tilray (TLRY) inks an import deal with the U.S. Drug Enforcement Administration for a trial on neurological movement disorder.

  • Benzinga5 days ago

    Surface Oncology Offers 'Robust Pipeline,' Baird Says In Bullish Initiation

    In the next few years, Ulz said he anticipates "meaningful upside" stemming from early clinical data on antibodies that inhibit CD47, such as SRF231. The drug has broad utility and a differentiated safety profile, Ulz said. A Novartis AG (NYSE: NVS) partnership should target the adenosine pathway, leading to immunosuppression, Ulz said.

  • The Wall Street Journal5 days ago

    [$$] Novartis' CAR-T Drug Hits First Setback in Europe

    AG’s (NOVN.EB) immunotherapy Kymriah is too expensive to be recommended for use in adults with B-cell lymphoma that have relapsed or haven’t responded to first-line treatment, a U.K. regulator said Wednesday, despite the Swiss pharma giant offering a discount on its hefty list price--the first major setback for the company’s drug in Europe. The National Institute for Health and Care Excellence earlier this month recommended the therapy for use in pediatric patients with a different kind of blood cancer. In a statement, NICE recognized that Kymriah had significant clinical benefits, with response rates of about 40% in two studies, and overall survival rates of about one to two years.

  • UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
    Reuters5 days ago

    UK rejects adult Novartis CAR-T therapy, after 'yes' in kids

    Health authorities in England have rejected a pricey CAR-T cell therapy from Novartis for adults with blood cancer, two weeks after endorsing its use in children and young people. The National Institute for Health and Care Excellence (NICE) said Kymriah was not cost-effective for adult lymphoma. The decision on Kymriah in adults is in line with the rejection of a rival CAR-T treatment for adult lymphoma from Gilead Sciences.

  • Reuters5 days ago

    UK rejects adult Novartis CAR-T therapy, after 'yes' in kids

    Health authorities in England have rejected a pricey CAR-T cell therapy from Novartis for adults with blood cancer, two weeks after endorsing its use in children and young people. The National Institute for Health and Care Excellence (NICE) said Kymriah was not cost-effective for adult lymphoma. The decision on Kymriah in adults is in line with the rejection of a rival CAR-T treatment for adult lymphoma from Gilead Sciences.

  • Novartis Cancer Therapy Kymriah Hits First Hurdle in Europe
    Bloomberg5 days ago

    Novartis Cancer Therapy Kymriah Hits First Hurdle in Europe

    Novartis AG’s cancer drug Kymriah faced its first setback in Europe as U.K. health authorities made an initial recommendation against paying for the breakthrough therapy to treat a form of lymphoma in adults. Although the one-time treatment has demonstrated significant benefits, and Novartis had offered an undisclosed discount on the list price of 282,000 pounds ($372,000), Kymriah isn’t adequately cost-effective for routine funding, the National Institute for Health and Care Excellence said in a statement Wednesday. Novartis said it’s disappointed with the preliminary decision, and that it may be difficult to assess the value of new treatments like Kymriah that are aimed at curing lethal diseases.

  • Analysts Raise Ratings on Teva Stock on Ajovy’s FDA Approval
    Market Realist7 days ago

    Analysts Raise Ratings on Teva Stock on Ajovy’s FDA Approval

    On September 14, Teva Pharmaceutical Industries (TEVA) announced the FDA approval of Ajovy (fremanezumab), its injectable migraine drug. Following the news, a number of analysts raised their recommendations and target prices on Teva Pharmaceutical Industries.

  • Competition Dynamics for Ajovy—Teva’s Migraine Drug
    Market Realist7 days ago

    Competition Dynamics for Ajovy—Teva’s Migraine Drug

    Teva Pharmaceutical Industries (TEVA) received FDA approval for its Ajovy (fremanezumab-vfrm) injectable on September 14. The chart below shows the company’s quarterly sales trend. The marketing application for Ajovy was filed by Teva in Europe in February. Teva’s (TEVA) Ajovy is an anti-CGRP (calcitonin gene-related peptide) migraine prevention treatment and offers monthly and quarterly dosage options.

  • Novartis links bonuses to ethics in bid to rebuild reputation
    Reuters7 days ago

    Novartis links bonuses to ethics in bid to rebuild reputation

    Swiss drugmaker Novartis (NOVN.S) has revealed its employees only get a bonus if they meet or exceed expectations for ethical behavior as it seeks to address past shortcomings that have damaged its reputation. Chief Executive Vas Narasimhan has made strengthening the Swiss drugmaker's ethics culture a priority after costly bribery scandals or legal settlements in South Korea, China and the United States. Receiving a 2, which Novartis said denotes meeting expectations, or a 3, for "role model" behavior, would make them eligible for a bonus of up to 35 percent of their total compensation.

  • Reuters7 days ago

    Novartis links bonuses to ethics in bid to rebuild reputation

    Swiss drugmaker Novartis (NOVN.S) has revealed its employees only get a bonus if they meet or exceed expectations for ethical behaviour as it seeks to address past shortcomings that have damaged its reputation. Chief Executive Vas Narasimhan has made strengthening the Swiss drugmaker's ethics culture a priority after costly bribery scandals or legal settlements in South Korea, China and the United States. Receiving a 2, which Novartis said denotes meeting expectations, or a 3, for "role model" behaviour, would make them eligible for a bonus of up to 35 percent of their total compensation.

  • TheStreet.com7 days ago

    Teva Shares Pop as FDA Approves Its Migraine Drug

    American depository receipts jumped in morning trading on Monday, Sept. 17, following the news late Friday that the company had clinched the U.S. Food and Drug Administration's nod for its migraine drug. It is the second anti-calcitonin gene-related peptide (CGRP) drug approved by the agency to prevent migraines, after Amgen Inc. CGRP is thought to play a key role in causing migraine headaches.

  • Lenvima Could Significantly Boost Merck’s Revenue Growth
    Market Realist7 days ago

    Lenvima Could Significantly Boost Merck’s Revenue Growth

    In August, the FDA approved Merck’s (MRK) and Eisai’s Lenvima in the first-line setting for the treatment of individuals with unresectable hepatocellular carcinoma (or HCC). The FDA’s approval of Lenvima in the first-line setting for the treatment of HCC was based on data from the REFLECT trial.

  • How Is Merck’s Keytruda Positioned in September?
    Market Realist7 days ago

    How Is Merck’s Keytruda Positioned in September?

    Merck’s (MRK) Keytruda has witnessed ~89% YoY (year-over-year) growth and generated second-quarter revenues of $1.7 billion. In the US market, Keytruda’s second-quarter revenues grew 73.0% to reach $959.0.0 million. In the international markets, Keytruda’s revenues increased ~118.0% YoY to reach $707.0.0 million.

  • How Spark Therapeutics Is Positioned in 2018
    Market Realist10 days ago

    How Spark Therapeutics Is Positioned in 2018

    Spark Therapeutics (ONCE) is a gene therapy company focused on developing one-time treatments that are life-altering for genetic disease patients. Spark Therapeutics has a licensing and commercialization agreement with Novartis (NVS) for its investigational voretigene neparvovec. Spark Therapeutics has two gene therapy product candidates in its pipeline: SPK-7001 and SPK-8011.

  • Benzinga11 days ago

    The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 12). Inogen Inc (NASDAQ: INGN ) Kezar Life Sciences Inc ...

  • Zacks12 days ago

    KemPharm Posts Positive Top-Line Results on KP415 Prodrug

    KemPharm (KMPH) reports positive top-line results from second of three HAP studies on serdexmethylphenidate/KP415 Prodrug, which is contained in lead candidate KP415 that is being developed for ADHD.

  • Alcon to Set Up Future Global Headquarters in Geneva
    Market Realist13 days ago

    Alcon to Set Up Future Global Headquarters in Geneva

    Alcon, the eyecare business of Novartis (NVS), includes surgical products and vision care products. It announced today that it will locate its future headquarters in Geneva after spinning off from Novartis.

  • Alcon shifting global HQ from Fort Worth to Geneva
    American City Business Journals13 days ago

    Alcon shifting global HQ from Fort Worth to Geneva

    Alcon, one of Fort Worth's biggest companies, is shifting its global headquarters to Geneva after the completion of the eye product firm’s spinoff from parent company Novartis, the companies announced today.